These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

171 related articles for article (PubMed ID: 21415927)

  • 1. Dose-levels and first signs of efficacy in contemporary oncology phase 1 clinical trials.
    Ferte C; Soria JC; Penel N
    PLoS One; 2011 Mar; 6(3):e16633. PubMed ID: 21415927
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Phase I oncology studies: evidence that in the era of targeted therapies patients on lower doses do not fare worse.
    Jain RK; Lee JJ; Hong D; Markman M; Gong J; Naing A; Wheler J; Kurzrock R
    Clin Cancer Res; 2010 Feb; 16(4):1289-97. PubMed ID: 20145187
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Dose-response relationship in phase i clinical trials: a European Drug Development Network (EDDN) Collaboration Study.
    Moreno García V; Olmos D; Gomez-Roca C; Cassier PA; Morales-Barrera R; Del Conte G; Gallerani E; Brunetto AT; Schöffski P; Marsoni S; Schellens JH; Penel N; Voest E; Evans J; Plummer R; Wilson RH; Soria JC; Tabernero J; Verweij J; Kaye SB
    Clin Cancer Res; 2014 Nov; 20(22):5663-71. PubMed ID: 25252757
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Meta-analysis of the relationship between dose and benefit in phase I targeted agent trials.
    Gupta S; Hunsberger S; Boerner SA; Rubinstein L; Royds R; Ivy P; LoRusso P
    J Natl Cancer Inst; 2012 Dec; 104(24):1860-6. PubMed ID: 23169991
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Relationship Between Response and Dose in Published, Contemporary Phase I Oncology Trials.
    Hazim A; Mills G; Prasad V; Haslam A; Chen EY
    J Natl Compr Canc Netw; 2020 Apr; 18(4):428-433. PubMed ID: 32259790
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Towards using a full spectrum of early clinical trial data: a retrospective analysis to compare potential longitudinal categorical models for molecular targeted therapies in oncology.
    Colin P; Micallef S; Delattre M; Mancini P; Parent E
    Stat Med; 2015 Sep; 34(22):2999-3016. PubMed ID: 26059319
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Predictors for establishing recommended phase 2 doses: analysis of 320 dose-seeking oncology phase 1 trials.
    Penel N; Duhamel A; Adenis A; Devos P; Isambert N; Clisant S; Bonneterre J
    Invest New Drugs; 2012 Apr; 30(2):653-61. PubMed ID: 21049280
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Early phase trial design for assessing several dose levels for toxicity and efficacy for targeted agents.
    Hoering A; Mitchell A; LeBlanc M; Crowley J
    Clin Trials; 2013; 10(3):422-9. PubMed ID: 23529697
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Dose-finding designs for trials of molecularly targeted agents and immunotherapies.
    Chiuzan C; Shtaynberger J; Manji GA; Duong JK; Schwartz GK; Ivanova A; Lee SM
    J Biopharm Stat; 2017; 27(3):477-494. PubMed ID: 28166468
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Assessment of various continual reassessment method models for dose-escalation phase 1 oncology clinical trials: using real clinical data and simulation studies.
    James GD; Symeonides S; Marshall J; Young J; Clack G
    BMC Cancer; 2021 Jan; 21(1):7. PubMed ID: 33402104
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Phase I trial design: are new methodologies being put into practice?
    Dent SF; Eisenhauer EA
    Ann Oncol; 1996 Aug; 7(6):561-6. PubMed ID: 8879368
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Design considerations for dose-expansion cohorts in phase I trials.
    Iasonos A; O'Quigley J
    J Clin Oncol; 2013 Nov; 31(31):4014-21. PubMed ID: 24101039
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Pediatric phase I trials in oncology: an analysis of study conduct efficiency.
    Lee DP; Skolnik JM; Adamson PC
    J Clin Oncol; 2005 Nov; 23(33):8431-41. PubMed ID: 16293874
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Optimal Dosing for Targeted Therapies in Oncology: Drug Development Cases Leading by Example.
    Sachs JR; Mayawala K; Gadamsetty S; Kang SP; de Alwis DP
    Clin Cancer Res; 2016 Mar; 22(6):1318-24. PubMed ID: 26597302
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Beyond the dose-limiting toxicity period: Dermatologic adverse events of patients on phase 1 trials of the Cancer Therapeutics Evaluation Program.
    Drilon A; Eaton AA; Schindler K; Gounder MM; Spriggs DR; Harris P; Ivy SP; Iasonos A; Lacouture ME; Hyman DM
    Cancer; 2016 Apr; 122(8):1228-37. PubMed ID: 26916138
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Challenges of phase 1 clinical trials evaluating immune checkpoint-targeted antibodies.
    Postel-Vinay S; Aspeslagh S; Lanoy E; Robert C; Soria JC; Marabelle A
    Ann Oncol; 2016 Feb; 27(2):214-24. PubMed ID: 26578728
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Competing designs for drug combination in phase I dose-finding clinical trials.
    Riviere MK; Dubois F; Zohar S
    Stat Med; 2015 Jan; 34(1):1-12. PubMed ID: 24464821
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Choice of starting dose for molecularly targeted agents evaluated in first-in-human phase I cancer clinical trials.
    Le Tourneau C; Stathis A; Vidal L; Moore MJ; Siu LL
    J Clin Oncol; 2010 Mar; 28(8):1401-7. PubMed ID: 20124167
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Lessons Learned: Dose Selection of Small Molecule-Targeted Oncology Drugs.
    Bullock JM; Rahman A; Liu Q
    Clin Cancer Res; 2016 Jun; 22(11):2630-8. PubMed ID: 27250934
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Seamless phase I-II trial design for assessing toxicity and efficacy for targeted agents.
    Hoering A; LeBlanc M; Crowley J
    Clin Cancer Res; 2011 Feb; 17(4):640-6. PubMed ID: 21135145
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 9.